Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial-Reference-Cited by-同舟云学术

Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial

Published:2017-05 Issue:5 Volume:2 Page:337-346
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Bachet Jean-Baptiste,Hammel Pascal,Desramé Jérôme,Meurisse Aurélia,Chibaudel Benoist,André Thierry,Debourdeau Philippe,Dauba Jérome,Lecomte Thierry,Seitz Jean-François,Tournigand Christophe,Aparicio Thomas,Meyer Véronique Guerin,Taieb Julien,Volet Julien,Monier Amandine,Bonnetain Franck,Louvet Christophe

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference30 articles.

1. Annual report to the nation on the status of cancer, 1975–2008, featuring cancers associated with excess weight and lack of sufficient physical activity;Eheman;Cancer,2012

2. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States;Rahib;Cancer Res,2014

3. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry;Carpelan-Holmstrom;Gut,2005

4. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

5. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group;Moore;J Clin Oncol,2007

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study;The Oncologist;2024-06-21

2. The estimand framework had implications in time to patient-reported outcomes deterioration analyses in cancer clinical trials;Journal of Clinical Epidemiology;2023-10

3. Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety;Biomedicines;2023-07-15

5. S3-Leitlinie zum exokrinen Pankreaskarzinom – Langversion 2.0 – Dezember 2021 – AWMF-Registernummer: 032/010OL;Zeitschrift für Gastroenterologie;2022-11